RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Shantou University Medical College hospitals; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Shantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07339488, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.

    Inclusion criterion 4

  3. ECOG performance status score of 0-1.

    Inclusion criterion 3

  4. WBC≥3×10⁹/L

    Inclusion criterion 12

    ALT and AST≤2.5×ULN

    Inclusion criterion 13

    TBIL≤1.5×ULN

    Inclusion criterion 14

    SCr≤1.5×ULN; or CrCl≥60 mL/min Coagulation: APTT, INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3/FT4 levels should also be considered; eligible if FT3/FT4 are normal) Echocardiography: LVEF≥50%

    Inclusion criterion 15

  5. Active hepatitis B, hepatitis C, HIV, or syphilis.

    Exclusion criterion 8

  6. Female subjects need to agree to use contraception during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study.

    Inclusion criterion 16

    Pregnant or lactating women.

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07339488, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients voluntarily enroll in this study, sign an informed consent form, and demonstrate good compliance.
  • Age ≥18 years and ≤75 years; both sexes are eligible.
  • ECOG performance status score of 0-1.
  • Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.
  • Thoracic esophageal cancer.
  • Unresectable lesions, defined as: T4 stage; Borderline resectable T3 disease, in which imaging cannot exclude invasion of adjacent organs or structures, such as the trachea, bronchi, or aorta; T3 disease with supraclavicular lymph node metastasis; or clinically confirmed unresectable disease by the surgeon.
  • No prior history of anti-tumor treatment, including chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.
  • Baseline laboratory requirements (within 7 days prior to enrollment):

Hematology:

  • Hb≥90 g/L (no transfusion within 14 days)
  • NEUT ≥1.5×10⁹/L
  • PLT ≥100×10⁹/L
  • WBC≥3×10⁹/L

Biochemistry:

  • ALT and AST≤2.5×ULN
  • TBIL≤1.5×ULN
  • SCr≤1.5×ULN; or CrCl≥60 mL/min Coagulation: APTT, INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3/FT4 levels should also be considered; eligible if FT3/FT4 are normal) Echocardiography: LVEF≥50%
  • Female subjects need to agree to use contraception during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study.
  • No psychological, familial, social, or geographical factors that may impair protocol adherence.
  • Other parameters meet general clinical trial enrollment criteria.
  • The subject or authorized representative has read, fully understands the patient information sheet, and signed the informed consent form.

Exclusion Criteria:

  • Patients with distant metastases other than supraclavicular lymph node metastases.
  • Presence or high risk of esophageal perforation.
  • Patients with contraindications to radiotherapy or immune checkpoint inhibitor (ICI) therapy.
  • Subjects with active, uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment.
  • Respiratory depression, airway obstruction, or tissue hypoxia.
  • Severe cardiac disease (i.e., NYHA functional class II or higher).
  • Markedly abnormal liver or kidney function (i.e., indicators >3 times the upper limit of normal).
  • Active hepatitis B, hepatitis C, HIV, or syphilis.
  • Active brain disease or central nervous system/meningeal metastases with significant symptoms, or impaired decision-making capacity.
  • Hypersensitivity to drugs included in the trial.
  • Drug and/or alcohol abuse.
  • Pregnant or lactating women.
  • Concurrent participation in another therapeutic clinical trial.
  • Major surgical procedure within 30 days prior to enrollment.
  • Use of antibiotics, antifungals, antivirals, or antiparasitics within 4 weeks prior to registration.

Quoted from ClinicalTrials.gov, NCT07339488, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07339488, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07339488